Fibronectin-binding Peptides for Use in Tumor or Fibrosis Diagnosis and Therapy

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes a new class of fibronectin-binding peptides with improved affinity and biodistribution characteristics, designed for use in the diagnosis and treatment of diseases associated with abnormal fibronectin accumulation, such as cancer and fibrosis. These peptides can be further conjugated to therapeutic or diagnostic payloads, including drugs and imaging agents, allowing targeted delivery or visualization of disease sites characterized by high levels of fibronectin. The invention provides both specific peptide sequences and methods for their use in pharmaceutical compositions and diagnostic assays.

Use CasesContent extracted from patent full text and abstract with AI.

• Targeted therapy for various cancers including breast, prostate, renal, pancreatic, lung, and head and neck cancers by delivering cytotoxic agents directly to the tumor site via the fibronectin-binding peptide.
• Diagnosis and imaging of fibrotic diseases (e.g., pulmonary, liver, and kidney fibrosis) using peptide-based imaging agents attached to the fibronectin-binding peptides.
• Targeted drug delivery in autoimmune diseases such as systemic sclerosis, type 1 diabetes, Graves’ disease, multiple sclerosis, and rheumatoid arthritis.
• Detection and monitoring of pathological fibronectin accumulation in diseases such as atherosclerosis and lymphedema using labeled peptides for imaging techniques like SPECT, PET, MRI, or fluorescence microscopy.
• Therapeutic intervention to inhibit tumor growth, angiogenesis, or fibrotic progression by delivering therapeutic payloads such as cytokines, apoptosis modulators, or anti-proliferative drugs via the peptides.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables highly specific targeting of drugs or imaging agents to tissues with pathological fibronectin accumulation, reducing off-target effects and improving therapeutic efficacy.
• Peptides show improved tumor uptake and reduced accumulation in non-target organs (liver, spleen) compared to prior art, offering a better therapeutic index.
• Versatile platform: the peptides can be conjugated to a wide range of therapeutics (cytotoxics, cytokines, inhibitors) or diagnostic agents (imaging isotopes, fluorescent dyes).
• Improved metabolic stability and biodistribution profiles maximize the effectiveness of both diagnostic and therapeutic interventions.
• Potential to improve early detection, diagnosis, and treatment outcomes in cancers and fibrotic diseases, as well as enable non-invasive disease monitoring.
• Reduces adverse side effects by enabling lower drug dosages and minimizing exposure to healthy tissues.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to fibronectin-binding peptides according to the sequence Fnl5BS - L1 - Fnl4BS - L2 - Fnl3BS - L3 - Fnl2BS which are useful in tumor or fibrosis diagnosis and therapy. Instant peptides show improved fibronectin-binding and biodistribution properties compared to the prior art. Furthermore, instant peptides may be conjugated to a payload and are useful in the treatment and/or prevention of diseases associated with pathological fibronectin accumulation, including cancer and fibrosis. Instant peptides are also useful in diagnosis of diseases associated with pathological fibronectin accumulation, including cancer and fibrosis.